Zolbetuximab-clzb Receives FDA Approval for Treatment of Advanced Gastric and GEJ Adenocarcinoma Alexandra Gerlach, Associate Editor September 26th 2024 Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment October 19th 2024 Survey: Wome...
In 2021, these findings led the EMA to approve nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastaticgastric adenocarcinomawhose tumors express PD-L1 with a CPS ≥ 5. The FDA also approv...
March 5th 2025 Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward March 4th 2025 FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCCLatest Conference Coverage Dr Coombs on the Challenges in Establishing a Treatment Consensus...